Faites connaître cette offre !
Reference : UMR7258-EDDPAS-003
Workplace : MARSEILLE,MARSEILLE 08
Date of publication : Thursday, October 08, 2020
Type of Contract : FTC Scientist
Contract Period : 6 months
Expected date of employment : 2 November 2020
Proportion of work : Full time
Remuneration : between 2728.26 and 3145.68€ (pre-tax) monthly depending on the leverl of experience
Desired level of education : PhD
Experience required : Indifferent
The candidate will be in charge of executing parts of the HITCH project, funded by the French National Cancer Institute. This project relies on an innovative combination of high-throughput drug and siRNA screening based on synthetic lethality and drug repurposing principles. This approach will identify already-approved drugs that can increase the efficacy of current standard of care and experimental treatments for glioblastoma, the most common and malignant primary brain tumour. This project will provide clinicians with novel therapeutic options whose efficacy will be evaluated in subsequent clinical trials. The second innovative development of this project resides in the use of click chemistry-based proteomics and imaging to rapidly pinpoint the key molecular targets of repurposed drugs in the context of glioblastoma treatment. This will further facilitate clinical translation by unveiling reliable biomarkers for patient selection.
The candidate will be in charge of undertaking the experiments of clicl chemistry coupled with microscopie and mass spectrometry to unveil the non-canonical targets of repurposed drugs. Then, she/he will perform a functional analysis of these novel targets in glioblastoma cells.
The candidate will need to hold a PhD in Life and/or Health Sciences (e.g. Oncology, Biology, Pharmacology) and be familiar with:
- Cell culture (both 2D and 3D)
- Functional genomics
- Click chemistry
- Fluorescence microscopy
- Mass spectrometry
The Cancer Research Center of Marseille (CRCM) affiliated to Inserm (UMR1068), CNRS (UMR7258) and Aix-Marseille University (UM105) is an original center in the landscape of French research. This originality is not only due to its location in the heart of the Institut Paoli-Calmettes (IPC) but also to his vocation: to advance the biology and medicine of cancer while working at the physiological and pathological interface, the fundamental and the applied, research and the clinic. This continuum between basic research, translational research and clinical research is really the hallmark of the CRCM. The “integrative Structural and Chemical Biology” Team (iSCB), led by Drs Yves Collette and Xavier Morelli, aims at developing multi-disciplinary approaches to identify, characterize and target “druggable” protein-protein interactions in oncology. The group led by Dr Eddy Pasquier within iSCB uses reverse molecular pharmacology to identify novel therapeutic targets in refractory cancers. In particular, they apply high-throughput screening of drug and RNAi libraries to unveil key factors involved in drug resistance in tumors of the central and peripheral nervous system.
We talk about it on Twitter!